論文

国際誌
2021年12月3日

Dual inhibition of TMPRSS2 and Cathepsin Bprevents SARS-CoV-2 infection in iPS cells.

Molecular therapy. Nucleic acids
  • Rina Hashimoto
  • ,
  • Ayaka Sakamoto
  • ,
  • Sayaka Deguchi
  • ,
  • Renxing Yi
  • ,
  • Emi Sano
  • ,
  • Akitsu Hotta
  • ,
  • Kazutoshi Takahashi
  • ,
  • Shinya Yamanaka
  • ,
  • Kazuo Takayama

26
開始ページ
1107
終了ページ
1114
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.omtn.2021.10.016

It has been reported that many receptors and proteases are required for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Although angiotensin-converting enzyme 2 (ACE2) is the most important of these receptors, little is known about the contribution of other genes. In this study, we examined the roles of neuropilin-1, basigin, transmembrane serine proteases (TMPRSSs), and cathepsins (CTSs) in SARS-CoV-2 infection using the CRISPR interference system and ACE2-expressing human induced pluripotent stem (iPS) cells. Double knockdown of TMPRSS2 and cathepsin B (CTSB) reduced the viral load to 0.036% ± 0.021%. Consistently, the combination of the CTPB inhibitor CA-074 methyl ester and the TMPRSS2 inhibitor camostat reduced the viral load to 0.0078% ± 0.0057%. This result was confirmed using four SARS-CoV-2 variants (B.1.3, B.1.1.7, B.1.351, and B.1.1.248). The simultaneous use of these two drugs reduced viral load to less than 0.01% in both female and male iPS cells. These findings suggest that compounds targeting TMPRSS2 and CTSB exhibit highly efficient antiviral effects independent of gender and SARS-CoV-2 variant.

リンク情報
DOI
https://doi.org/10.1016/j.omtn.2021.10.016
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34692233
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527102
ID情報
  • DOI : 10.1016/j.omtn.2021.10.016
  • PubMed ID : 34692233
  • PubMed Central 記事ID : PMC8527102

エクスポート
BibTeX RIS